Laparoscopic versus open kidney removal: comparing outcomes and costs

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional comparison enrolls patients who require simple, partial (≤7 cm), or radical nephrectomy and assigns them to either laparoscopic or open surgical approaches. Key outcomes measured include operative time, blood loss, length of hospital stay, complications, and a detailed cost analysis. Eligible patients are adults fit for general anesthesia (ASA 1–3) without metastatic disease or emergency indications, and those with prior extensive ipsilateral retroperitoneal surgery are excluded. The procedures and follow-up are conducted at Menoufia Faculty of Medicine, with results intended to reflect clinical and economic performance in that setting.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* American Society of Anesthesiology score 1-3.
* Indication for :

  * Simple total nephrectomy or hemi nephrectomy: benign chronic inflammatory non-functioning kidney
  * Partial nephrectomy: localized renal mass ≤7 cm suitable for nephron-sparing surgery.
  * Radical nephrectomy or Radical nephrouretrectomy with bladder cuff: localized renal tumor requiring complete nephrectomy without major vascular invasion.
* Patient deemed fit for general anesthesia and surgery.
* Patient provides written informed consent.

Exclusion Criteria:

* emergency surgery, dialysis-dependent patients, planned hybrid procedures.
* Patients with incomplete data
* Patients with metastatic disease at presentation.
* Prior extensive ipsilateral retroperitoneal surgery or severe adhesions precluding Laparoscopy.
* Need for concomitant major procedures (eg, large bowel resection) at index operation.
* Locally advanced tumor with obvious major vascular involvement requiring complex vascular reconstruction.
* Uncorrected coagulopathy.
* Pregnancy or Obese patient (BMI \> 40)
* Inability to provide informed consent or comply with follow-up.

Where it's running

• Menoufia Faculty of Medicine
  Shibīn al Kawm, Shebin Elkom, Egypt Recruiting

Study contacts

• Study coordinator: Haitham Badr Elnaggar
• Email: naggarheso@gmail.com
• Phone: 01003247485

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Nectin-4 PET/CT imaging to differentiate renal tumors

  This study tests a new PET tracer, 18F-N230A, to see if it helps distinguish renal cell carcinoma from renal pelvic urothelial carcinoma in adults.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07875959

• Weight-loss programs to slow kidney cancer progression in small renal masses on active surveillance

  This study tests two weight-loss approaches, daily calorie restriction and 5:2 intermittent fasting, to see if they help people with small kidney tumors on active surveillance lose weight and potentially slow cancer progression.

  Recruiting Roswell Park Cancer Institute · Buffalo, New York · NCT07714018

• Predicting Toripalimab Response in High-Risk Recurrent Renal Cell Carcinoma using MRD

  This study tests whether measuring minimal residual disease after surgery can predict which high-risk RCC patients will benefit from adjuvant Toripalimab.

  Recruiting Tianjin Medical University Second Hospital · Tianjin, Tianjin Municipality · NCT07657325

• Safety and tolerability test of anti-CD70 T-cell therapy in advanced RCC

  This study tests a CD70-targeted CAR-T cell therapy in adults with advanced or metastatic renal cell carcinoma to see if it is safe and tolerable and to identify a usable dose for future studies.

  Recruiting Phase 1 Hrain Biotechnology Co., Ltd. · Shanghai · NCT07647744

• VMD-102 in liver cancer and other solid tumors

  This study tests VMD-102 to see if it is safe and tolerable and to find the best dose for further study in adults with advanced liver cancer and several other solid tumors.

  Recruiting at 2 sites Phase 1/2 VM Discovery, Inc. · Scottsdale, Arizona and 1 other locations · NCT07636785

• Registry of Minimally Invasive Cancer Treatments Using Spectral Angio-CT Guidance

  This registry collects data from adults undergoing image-guided, minimally invasive cancer treatments to see if spectral angio-CT guidance helps predict outcomes and improve planning.

  Recruiting Leiden University Medical Center · Lyon, Auvergne-Rhône-Alpes and 2 other locations · NCT07636148

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.